❌

Normal view

Received β€” 26 March 2026 ⏭

A Review of the Role of Zeqi Decoction in the Treatment of Non-Small Cell Lung Cancer

βœ‡Pulmonary nodule
By: Lan Zhang Β· Yanhui Jia Β· Lei Song Β· Yiman Li Β· Yawei Liu Β· Yan Qin Β· Tao Wang Β· Na Li
18 March 2026 at 18:00

J Multidiscip Healthc. 2026 Mar 11;19:584071. doi: 10.2147/JMDH.S584071. eCollection 2026.

ABSTRACT

Non-small cell lung cancer (NSCLC) is one of the malignant tumors with the highest incidence and mortality rates. Zeqi Decoction has the functions of "promoting diuresis and reducing swelling, resolving phlegm and dispersing nodules", embodying the unique approach of traditional Chinese medicine in treating lung cancer by "strengthening the body's resistance and eliminating pathogenic factors". Modern research shows that Zeqi Decoction exerts anti-NSCLC effects through multiple pathways and targets. In terms of the material basis of its efficacy, its active ingredients (such as diterpene esters and flavonoids contained in Zeqi) have the ability to directly inhibit the proliferation, invasion and migration of tumor cells and induce apoptosis. In terms of the mechanism of action, basic experiments have revealed that Zeqi Decoction can down-regulate the S100A9/STAT3 signaling pathway, inhibit the immunosuppressive activity of myelium-derived suppressor cells (MDSCs), reshape the tumor microenvironment, thereby enhancing the cytotoxic function of CD8⁺T cells, and can also regulate the EGFR/PI3K/Akt pathway to affect PD-L1 expression. Intervene in tumor immune escape; In terms of clinical transformation, the combination of Zexi Decoction with chemotherapy and targeted therapy can improve patients' symptoms such as cough and pleural effusion, prolong progression-free survival, and alleviate the toxic and side effects of Western medical treatment. In addition, Zexi Decoction also shows potential value in reversing drug resistance such as gemcitabine. At present, there are still problems such as the lack of standardized protocols and unclear molecular mechanisms in the research. In the future, it is necessary to combine new technologies such as network pharmacology and multi-omics analysis to deepen the research on the pharmacological material basis, dose-effect relationship and evidence-based medicine of Zeqi Decoction, so as to promote the clinical application and transformation of the combination of traditional Chinese and Western medicine in the treatment of NSCLC.

PMID:41847115 | PMC:PMC12991379 | DOI:10.2147/JMDH.S584071

Received β€” 5 March 2026 ⏭

PRAM-R: A Perception-Reasoning-Action-Memory Framework with LLM-Guided Modality Routing for Adaptive Autonomous Driving

βœ‡cs.AI, q-bio.NC updates on arXiv.org
By: Yi Zhang Β· Xian Zhang Β· Saisi Zhao Β· Yinglei Song Β· Chengdong Wu Β· Nenad Petrovic Β· Alois Knoll
5 March 2026 at 13:00
arXiv:2603.04222v1 Announce Type: cross Abstract: Multimodal perception enables robust autonomous driving but incurs unnecessary computational cost when all sensors remain active. This paper presents PRAM-R, a unified Perception-Reasoning-Action-Memory framework with LLM-Guided Modality Routing for adaptive autonomous driving. PRAM-R adopts an asynchronous dual-loop design: a fast reactive loop for perception and control, and a slow deliberative loop for reasoning-driven modality selection and memory updates. An LLM router selects and weights modalities using environmental context and sensor diagnostics, while a hierarchical memory module preserves temporal consistency and supports long-term adaptation. We conduct a two-stage evaluation: (1) synthetic stress tests for stability analysis and (2) real-world validation on the nuScenes dataset. Synthetic stress tests confirm 87.2% reduction in routing oscillations via hysteresis-based stabilization. Real-world validation on nuScenes shows 6.22% modality reduction with 20% memory recall while maintaining comparable trajectory accuracy to full-modality baselines in complex urban scenarios. Our work demonstrates that LLM-augmented architectures with hierarchical memory achieve efficient, adaptive multimodal perception in autonomous driving.

MedFeat: Model-Aware and Explainability-Driven Feature Engineering with LLMs for Clinical Tabular Prediction

βœ‡cs.AI, q-bio.NC updates on arXiv.org
By: Zizheng Zhang Β· Yiming Li Β· Justin Xu Β· Jinyu Wang Β· Rui Wang Β· Lei Song Β· Jiang Bian Β· David W Eyre Β· Jingjing Fu
4 March 2026 at 13:00
arXiv:2603.02221v1 Announce Type: cross Abstract: In healthcare tabular predictions, classical models with feature engineering often outperform neural approaches. Recent advances in Large Language Models enable the integration of domain knowledge into feature engineering, offering a promising direction. However, existing approaches typically rely on a broad search over predefined transformations, overlooking downstream model characteristics and feature importance signals. We present MedFeat, a feedback-driven and model-aware feature engineering framework that leverages LLM reasoning with domain knowledge and provides feature explanations based on SHAP values while tracking successful and failed proposals to guide feature discovery. By incorporating model awareness, MedFeat prioritizes informative signals that are difficult for the downstream model to learn directly due to its characteristics. Across a broad range of clinical prediction tasks, MedFeat achieves stable improvements over various baselines and discovers clinically meaningful features that generalize under distribution shift, demonstrating robustness across years and from ICU cohorts to general hospitalized patients, thereby offering insights into real-world deployment. Code required to reproduce our experiments will be released, subject to dataset agreements and institutional policies.
There are no more articles
❌